



# Protein kinase CK2 is required for Wntless internalization and Wnt secretion



Reinoud E.A. de Groot, Sophia B. Rappel, Magdalena J. Lorenowicz, Hendrik C. Korswagen \*

Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences, University Medical Centre Utrecht, Uppsalaalaa 8, 3584CT Utrecht, The Netherlands

## ARTICLE INFO

### Article history:

Received 22 April 2014

Received in revised form 14 August 2014

Accepted 18 August 2014

Available online 27 August 2014

### Keywords:

Protein kinase CK2

*C. elegans*

Endocytosis

Wntless

Wnt secretion

## ABSTRACT

Wnt proteins are lipid modified signaling molecules that have essential functions in development and adult tissue homeostasis. Secretion of Wnt is mediated by the transmembrane protein Wntless, which binds Wnt and transports it from the endoplasmic reticulum to the cell surface for release. To maintain efficient Wnt secretion, Wntless is recycled back to the Golgi and the endoplasmic reticulum through endocytosis and retromer dependent endosome to Golgi transport. We have previously identified protein kinase CK2 (CK2) in a genome-wide screen for regulators of Wnt signaling in *Caenorhabditis elegans*. Here, we show that CK2 function is required in Wnt producing cells for Wnt secretion. This function is evolutionarily conserved, as inhibition of CK2 activity interferes with Wnt5a secretion from mammalian cells. Mechanistically, we show that inhibition of CK2 function results in enhanced plasma membrane localization of Wls in *C. elegans* and mammalian cells, consistent with the notion that CK2 is involved in the regulation of Wls internalization.

© 2014 Elsevier Inc. All rights reserved.

## 1. Introduction

Wnt proteins are members of an evolutionarily conserved family of signaling proteins that have important functions in development and adult tissue homeostasis [1]. The mechanism of Wnt signaling has been the focus of intense investigation for over 30 years. This research has yielded a detailed understanding of the molecular mechanisms of Wnt signal transduction [2]. Wnt signaling can be categorized into a  $\beta$ -catenin dependent Wnt signal transduction route that revolves around the central effector protein  $\beta$ -catenin, which interacts with TCF transcription factors to control the expression of Wnt target genes. Next to this 'canonical' Wnt signal transduction cascade, Wnt proteins can induce  $\beta$ -catenin independent signal transduction pathways [3]. How Wnt proteins are produced and secreted from Wnt sending cells is however much less well understood [4].

Wnt proteins are cysteine-rich secreted proteins with a molecular mass of approximately 40 kDa. Wnts are lipid modified in the endoplasmic reticulum (ER) by the acyl transferase Porcupine [5] and require a specialized secretion pathway that depends on the transmembrane protein Wntless (Wls) to be released from Wnt producing cells [6–8]. It has recently been shown that Wls binds Wnt in the ER and escorts it through the Golgi network to the plasma membrane for release [9]. Next, Wls is retrieved back to the Golgi and the ER to take part in new rounds of Wnt secretion through a retrograde trafficking pathway that involves internalization of Wls from the plasma membrane and

retromer dependent transport from endosomes to the trans-Golgi network (TGN) [9–15]. The abrogation of retrograde trafficking and the concomitant lysosomal degradation of Wls cause defects in Wnt secretion and Wnt signaling.

Genetic screens in *Caenorhabditis elegans* have identified genes that are involved in retrograde trafficking of Wls [13,16–18]. The endocytosis of Wls requires the AP2 clathrin adaptor complex, while the transport of Wls from endosomes to the TGN requires the sorting nexin SNX-3 and the cargo selective subcomplex of the retromer complex, which consists of subunits encoded by the genes *vps-29*, *vps-26* and *vps-35*.

We previously identified the  $\beta$ -subunit of the serine–threonine protein kinase CK2 in a genome-wide RNAi screen for novel regulators of Wnt signaling in *C. elegans* [17]. Protein kinase CK2 is implicated in a plethora of biological processes, ranging from the regulation of apoptosis and proliferation to circadian rhythms and signal transduction (reviewed in [19]). Importantly, CK2 has been shown to positively regulate Wnt signaling. CK2 phosphorylates the TCF transcription factor LEF1 [20] and in this way regulates  $\beta$ -catenin dependent transcription. Furthermore, CK2 has been shown to modulate the proteasomal degradation of  $\beta$ -catenin by the phosphorylation of Thr292 of  $\beta$ -catenin [21]. In addition, CK2 can phosphorylate the cytoplasmic Wnt pathway component Disheveled (Dvl) [22]. Dvl is the bifurcation point between  $\beta$ -catenin dependent and  $\beta$ -catenin independent Wnt signal transduction routes and CK2 dependent phosphorylation of Dvl has been proposed to influence both  $\beta$ -catenin dependent and  $\beta$ -catenin independent Wnt signaling [22,23]. In this study, we show that CK2 also has an evolutionary conserved role in Wnt producing cells, where it acts at the level of Wls internalization at the plasma membrane.

\* Corresponding author. Tel.: +31 30 2121981; fax: +31 30 2516464.  
E-mail address: [r.korswagen@hubrecht.eu](mailto:r.korswagen@hubrecht.eu) (H.C. Korswagen).

## 2. Materials and methods

### 2.1. *C. elegans* strains and culture

*C. elegans* strains were cultured at 20 °C using standard conditions as described [24]. Mutant alleles and transgenes used were: *vps-29(tm1320)*, *mig-14(mu71)*, *muls32[Pmec-7::gfp]* [25], *huls60[Pegl-20::egl-20::protA]* [16], *huls72[Pmig-14::mig-14::gfp]* [15], *huSi2[Pmig-14::mig-14::gfp]* [17] and *huEx442[Pmig-14::kin-3(RNAi)]*.

### 2.2. *C. elegans* RNAi, transgenesis and imaging

Systemic RNAi by feeding and tissue-specific RNAi by transgene mediated expression of double-stranded RNA (dsRNA) were performed as described [26–28]. To express *kin-3* dsRNA from the *mig-14* promoter, 500 base pair (bp) fragments of coding sequence were PCR amplified from genomic DNA. After PCR fusion to the *mig-14* promoter (in the sense as well as the antisense orientation), the final PCR products were injected in *vps-29(tm1320)*; *muls32* animals at a concentration of 7 ng/μl with 7 ng/μl *Pmyo2::mCherry* injection marker and 150 ng/μl pBluescript plasmid DNA, yielding the transgene *huEx442[Pmig-14::kin-3(RNAi)]*.

The QLd migration phenotype was determined when the animals reached the young adult stage. The final position of the QL descendant PVM was scored relative to the vulva in young adult animals as described [25]. ALM polarity was determined in L4 larvae. Animals that displayed at least one ALM with reversed polarity were scored as defective. EGL-20::protA staining was performed as described [16]. MIG-14 protein levels were determined as described [17]. MIG-14 localization was imaged in young adult animals as described [15]. The subcellular localization of MIG-14 was scored blind by 5 lab members and the results were consistent among the different scorings. Antibodies used were anti-goat-Alexa647 (Life Technologies), anti-GFP (BD Livingcolors), anti-alpha-tubulin (Sigma) and anti-mouse-HRP (GE Healthcare).

### 2.3. Wnt5a secretion

Wnt5a expressing L cells and control L cells were cultured in DMEM with 10% FBS, 5% L-glutamine and 5% penicillin/streptomycin and grown to confluence in 12 well plates. Cells were washed with PBS and culture medium before incubation in culture medium supplemented with 50 μM TBB (Sigma) or DMSO for the indicated time. Conditioned medium was collected and centrifuged for 4 min at 2400 rpm before analysis by standard Western blotting techniques. Antibodies used: anti-Wnt5a (Cell signaling) and anti-rabbit-HRP (GE Healthcare).

### 2.4. Wls cell surface labeling

HEK293T cells were transfected with Wnt3a and cultured in DMEM with 10% FBS, 5% L-glutamine and 5% penicillin/streptomycin in 15 cm dishes. The culture medium was supplemented with 50 μM TBB (Sigma) or DMSO for 4 h prior to cell surface protein biotinylation using a commercially available kit (Pierce/Thermo) according to the manufacturer's instructions. Cell surface proteins were analyzed by Western blot. Antibodies used: anti-Wls (ab72385-500, Abcam), anti-transferrin-receptor (236-15375, Invitrogen), anti-GAPDH (GAPDH71.1, Sigma), anti-mouse-HRP (GE Healthcare), and anti-chicken-HRP (Abcam).

## 3. Results and discussion

### 3.1. CK2 is required for β-catenin dependent and β-catenin independent Wnt signaling in *C. elegans*

We identified *kin-10* in a genome-wide RNAi screen aimed at identifying novel regulators of Wnt signaling in *C. elegans* [17]. *kin-10* encodes

an ortholog of the regulatory β-subunit of protein kinase CK2. To characterize the function of *kin-10* in β-catenin dependent Wnt signaling, we analyzed the effect of *kin-10* knockdown on the Wnt dependent migration of the QL neuroblast descendants (QLd). During the first stage of larval development, QL and its three descendants (QLd) migrate from a position in the midbody to distinct positions in the posterior (Fig. 1A). This migration is dependent on the Wnt protein EGL-20, which induces a β-catenin dependent Wnt signal transduction cascade in QL, which results in the expression of the Hox gene *mab-5* [29,30]. *mab-5* in turn directs the migration of the QLd towards the posterior. When EGL-20 signaling is inhibited, *mab-5* expression fails to be induced and as a consequence, the QLd migrate in the opposite, anterior direction.

Since *kin-10* is an essential gene [31], we had to rely on partial knockdown to study the function of *kin-10* during post-embryonic development. For this reason, we used a sensitized genetic background to enhance Wnt signaling phenotypes. The background that we used is a mutation in the retromer subunit gene *vps-29*. In *vps-29* mutants, the secretion of EGL-20 is reduced, resulting in a partially penetrant defect in QLd migration [15,32]. Interfering with Wnt pathway components, or components of the Wnt secretion machinery such as the retromer component *vps-35*, strongly enhances this phenotype (Fig. 1B) [17,32]. We found that the knockdown of *kin-10* also resulted in a significant increase in the percentage of animals with anteriorly displaced QLd (Fig. 1B). When we subjected *vps-29* mutants to *kin-3* RNAi, which targets the catalytic α-subunit of CK2, we observed a comparable increase in the QLd migration phenotype (Fig. 1B), suggesting that the CK2 holoenzyme is required for β-catenin dependent Wnt signaling.


Next, we asked if knockdown of CK2 also inhibits β-catenin independent Wnt signaling in *C. elegans*. To this end, we investigated the polarity of the ALM neurons. The ALM neurons direct a long protrusion towards the anterior and a short protrusion posteriorly (Fig. 1C). This process is regulated by the Wnt proteins EGL-20 and CWN-1, but is independent of β-catenin [33,34]. Using a partial loss of function mutation of *mig-14*/Wls as a sensitized genetic background [15], we found that *kin-10* RNAi induces a significant increase in the percentage of animals with defects in ALM polarity (Fig. 1D). Taken together, these results show that *kin-10* is required for β-catenin dependent as well as β-catenin independent Wnt signaling in *C. elegans*.

### 3.2. CK2 is required for Wnt secretion in *C. elegans* and mammalian cells

The requirement of CK2 for both β-catenin dependent and β-catenin independent Wnt signaling indicates that CK2 acts upstream in the Wnt pathway, either at a proximal level in the Wnt signal transduction cascade or at the level of Wnt production and secretion in Wnt sending cells. To investigate whether CK2 is required in Wnt producing cells, we specifically knocked down *kin-3* in Wnt producing cells using transgene mediated RNAi [26] and investigated whether this affects the EGL-20 dependent migration of the QLd in the *vps-29* sensitized genetic background. As shown in Fig. 2A, we observed a mild, but significant increase in the percentage of animals with anteriorly displaced QLd, indicating that *kin-3* is required in Wnt producing cells.

To investigate whether CK2 is necessary for EGL-20/Wnt secretion, we visualized the EGL-20 gradient using a fusion of EGL-20 with the immunoglobulin binding region of protein A. Staining with fluorescently tagged IgG revealed a punctate gradient of EGL-20 that ranges from the producing cells in the tail to the midbody region [16]. We found that the EGL-20 gradient was markedly reduced when we subjected the animals to *kin-10* RNAi (Fig. 2B) indicating that CK2 is required for the secretion of the Wnt protein EGL-20 in *C. elegans*.

To investigate if the function of CK2 in Wnt secretion is evolutionary conserved, we chemically inhibited CK2 function in Wnt5a producing mouse L cells [35] using the specific CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) [36]. We found that the inhibition of CK2 resulted in a significant reduction in the amount of Wnt5a that is




**Fig. 1.** CK2 is required for Wnt signaling in *C. elegans*. (A) Schematic overview of QL descendant (QLd) migration, a read-out for β-catenin dependent Wnt signaling in *C. elegans*. (B) Knockdown of CK2 interferes with the β-catenin dependent posterior migration of the QL descendants in a *vps-29(tm1320)* sensitized mutant background (data are represented as mean ± SD and include results from 3 experiments,  $n > 30$  per experiment,  $*p = 6.5 \times 10^{-7}$  (control vs. *vps-35*),  $*p = 3.5 \times 10^{-6}$  (control vs. *kin-10*),  $*p = 1.2 \times 10^{-4}$  (control vs. *kin-3*) (Students t-test)). (C) Schematic overview of ALM polarity, a read-out for β-catenin independent Wnt signaling in *C. elegans*. (D) Knockdown of *kin-10* interferes with polarization of the ALM neuron in a *mig-14(mu71)* sensitized mutant background (data are represented as mean ± SD and include results from 3 experiments,  $n > 30$  per experiment,  $*p = 1.0 \times 10^{-3}$  (control vs. *vps-35*),  $p = 3.7 \times 10^{-6}$  (control vs. *kin-10*) (Students t-test)).

secreted into the culture medium (Fig. 2C), indicating that CK2 function is required for the secretion of Wnt proteins from mammalian cells.


### 3.3. CK2 is required for Wls internalization

Wnt secretion depends on the continuous shuttling of Wls between the Golgi and the plasma membrane [10,11,13–15]. We hypothesized

that CK2 may be involved in the regulation of Wls trafficking. The abrogation of retromer mediated retrograde transport of Wls from endosomes to the TGN causes missorting of Wls to lysosomes and Wls degradation [10,11,13–15,17]. CK2 has been implicated in retrograde trafficking of the cation-independent mannose-6-phosphate receptor (CI-MPR) [37]. CK2 is recruited by PACS-1 to phosphorylate the clathrin adapter GGA-3, which is necessary for endosome to TGN transport of



**Fig. 2.** CK2 function is required for Wnt secretion in *C. elegans* and mammalian cells. (A) Knockdown of *kin-3* in Wnt producing cells in *C. elegans* interferes with the EGL-20/Wnt dependent posterior migration of the QL descendants in a *vps-29(tm1320)* sensitized mutant background (data are represented as mean ± SD and include results from 5 experiments,  $n > 30$  per experiment,  $*p = 0.019$  (Students t-test)). (B) EGL-20::ProtA gradient stained with rabbit-anti-goat-Alexa647 in L1 larvae [16] subjected to control, *vps-35* or *kin-10* RNAi. Scale bar, 8 μm. (C) Western blot analysis of Wnt5a in the culture medium of mouse L-cells. The medium was conditioned for 20 h by control L cells or Wnt5a expressing L cells in presence of the CK2 inhibitor TBB (50 μM) or DMSO.



**Fig. 3.** CK2 controls Wls internalization. (A) MIG-14::GFP protein levels in L1 larvae subjected to control, *vps-35* or *kin-10* RNAi. (B) MIG-14::GFP localization (categorized in mostly punctate, intermediate or cortical localization) in L1 larvae subjected to control, *apa-2*, *vps-35* or *kin-10* RNAi. Scale bar, 4  $\mu$ m. (C) HEK293T cells were treated with TBB or DMSO prior to biotinylation of cell surface proteins. Subsequently, the cells were lysed and surface proteins were isolated by streptavidin affinity purification. Total cell lysate and cell surface proteins were analyzed by Western blot using antibodies that recognize Wntless (Wls), the cytoplasmic protein glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or the membrane protein Transferrin Receptor (TfR).

the CI-MPR. We investigated if CK2 is also required for retrograde trafficking of Wls, but we did not observe a decrease in steady state MIG-14/Wls protein levels in *C. elegans* larvae that were subjected to *kin-10* RNAi (Fig. 3A). In contrast, RNAi targeting the retromer component *vps-35* resulted in a clear reduction of MIG-14::GFP protein levels. This result suggests that CK2 does not control retrograde trafficking of Wls.

An alternative possibility is that CK2 is required for the internalization of MIG-14/Wls from the plasma membrane. The endocytosis of MIG-14/Wls requires the AP2 adaptin complex and the knockdown of the AP2  $\alpha$ -subunit gene *apa-2* results in increased cortical localization of a functional MIG-14::GFP fusion protein [13,15]. We investigated MIG-14::GFP localization in animals that were subjected to *kin-10* RNAi (Fig. 3B). The knockdown of *kin-10* resulted in increased cortical localization of MIG-14::GFP, similar to the knockdown of *apa-2*, suggesting that *kin-10* is required for MIG-14 internalization from the plasma membrane in *C. elegans*.

In an independent approach, we treated HEK293T cells with TBB to inhibit CK2 function. We biotinylated cell surface proteins using Sulfo-NHS-SS-Biotin and lysed the cells. Subsequently, we isolated the cell surface proteins by streptavidin affinity purification and detected endogenous Wls protein by Western blot. We discovered that treatment with the CK2 inhibitor caused increased plasma membrane localization of Wls (Fig. 3C). Taken together, these results support a model in which CK2 controls the internalization of MIG-14/Wls.

#### 4. Conclusions

In this work, we characterized the function of protein kinase CK2 in Wnt signaling. We identified CK2 in a genome-wide RNAi screen in *C. elegans* and showed that CK2 is required for both  $\beta$ -catenin dependent and  $\beta$ -catenin independent Wnt signaling. Using a tissue-specific RNAi approach, we demonstrated that CK2 is required in Wnt producing cells. Wnt secretion critically depends on the continuous cycling of Wls



between the ER, Golgi and the plasma membrane. When Wls internalization is blocked, Wls cannot return to the Golgi and ER to mediate transport of Wnt to the plasma membrane. As a consequence, Wnt secretion and Wnt signaling are perturbed [9,13,15]. In this study, we show that CK2 is required for Wls internalization in *C. elegans*, providing a mechanistic explanation for the positive role of CK2 in Wnt signaling that we observed. Importantly, our results are consistent with an evolutionarily conserved function of CK2 in Wnt secretion, as CK2 inhibition also resulted in reduced secretion of Wnt5a and increased plasma membrane localization of Wls in mammalian cells.

CK2 is known to phosphorylate several components of the endocytosis machinery [38,39]. For example, CK2 can phosphorylate the clathrin light chain,  $\beta$ -arrestin and subunits of the AP-2 adaptin complex [40–42]. Furthermore, CK2 is known to regulate the internalization of the EGFR through the phosphorylation of N-WASP and the regulation of actin dynamics [43]. CK2 may control Wls internalization by a similar mechanism, through the phosphorylation of the endocytosis machinery or the control of actin dynamics. Alternatively, CK2 may phosphorylate Wls directly and in this way control Wls internalization. However, we have not been able to demonstrate an interaction between CK2 and Wls, nor were we able to demonstrate CK2 mediated phosphorylation of Wls (data not shown).

Many reports have illustrated the importance of CK2 in promoting cell survival and proliferation (reviewed in [44]). CK2 is upregulated in several forms of cancer and cancer cells are particularly sensitive to inhibition of CK2 by small molecules. For this reason, CK2 is an appealing drug target. Following from our results, inhibiting CK2 may also be a fruitful approach in the treatment of tumors that are driven by excess Wnt production and secretion.

## Acknowledgments

We thank the members of the Korswagen group for critically reading the manuscript, the *Caenorhabditis* Genetics Center (University of Minnesota, Minneapolis) for the strains and the Hubrecht Imaging Center (HIC) for the assistance with microscopy. This work was funded by a grant from the Dutch Cancer Society (HUBR 2008-4114) (HCK).

## References

- [1] H. Clevers, *Cell* 127 (2006) 469–480.
- [2] B.T. MacDonald, K. Tamai, X. He, *Dev. Cell* 17 (2009) 9–26.
- [3] C. Niehrs, *Nat. Rev. Mol. Cell Biol.* 13 (2012) 767–779.
- [4] M.J. Lorenowicz, H.C. Korswagen, *Exp. Cell Res.* 315 (2009) 2683–2689.
- [5] T. Kadowaki, E. Wilder, J. Klingensmith, K. Zachary, N. Perrimon, *Genes Dev.* 10 (1996) 3116–3128.
- [6] C. Banziger, D. Soldini, C. Schutt, P. Zipperlen, G. Hausmann, K. Basler, *Cell* 125 (2006) 509–522.
- [7] K. Bartscherer, N. Pelte, D. Ingelfinger, M. Boutros, *Cell* 125 (2006) 523–533.
- [8] R.M. Goodman, S. Thombre, Z. Firtina, D. Gray, D. Betts, J. Roebuck, E.P. Spana, E.M. Selva, *Development* 133 (2006) 4901–4911.
- [9] J. Yu, J. Chia, C.A. Canning, C.M. Jones, F.A. Bard, D.M. Virshup, *Dev. Cell* 29 (2014) 277–291.
- [10] T.Y. Belenkaya, Y. Wu, X. Tang, B. Zhou, L. Cheng, Y.V. Sharma, D. Yan, E.M. Selva, X. Lin, *Dev. Cell* 14 (2008) 120–131.
- [11] X. Franch-Marro, F. Wendler, S. Guidato, J. Griffith, A. Baena-Lopez, N. Itasaki, M.M. Maurice, J.P. Vincent, *Nat. Cell Biol.* 10 (2008) 170–177.
- [12] I. Gasnereau, P. Herr, P.Z. Chia, K. Basler, P.A. Gleeson, *J. Biol. Chem.* 286 (2011) 43324–43333.
- [13] C.L. Pan, P.D. Baum, M. Gu, E.M. Jorgensen, S.G. Clark, G. Garriga, *Dev. Cell* 14 (2008) 132–139.
- [14] F. Port, M. Kuster, P. Herr, E. Furger, C. Banziger, G. Hausmann, K. Basler, *Nat. Cell Biol.* 10 (2008) 178–185.
- [15] P.T. Yang, M.J. Lorenowicz, M. Silhankova, D.Y. Coudreuse, M.C. Betist, H.C. Korswagen, *Dev. Cell* 14 (2008) 140–147.
- [16] D.Y. Coudreuse, G. Roel, M.C. Betist, O. Destree, H.C. Korswagen, *Science* 312 (2006) 921–924.
- [17] M. Harterink, F. Port, M.J. Lorenowicz, I.J. McGough, M. Silhankova, M.C. Betist, J.R. van Weering, R.G. van Heesbeen, T.C. Middelkoop, K. Basler, P.J. Cullen, H.C. Korswagen, *Nat. Cell Biol.* 13 (2011) 914–923.
- [18] B.C. Prasad, S.G. Clark, *Development* 133 (2006) 1757–1766.
- [19] F. Meggio, L.A. Pinna, *FASEB J.* 17 (2003) 349–368.
- [20] S. Wang, K.A. Jones, *Curr. Biol.* 16 (2006) 2239–2244.
- [21] D.H. Song, I. Dominguez, J. Mizuno, M. Kaut, S.C. Mohr, D.C. Seldin, *J. Biol. Chem.* 278 (2003) 24018–24025.
- [22] O. Bernatik, R.S. Ganji, J.P. Dijksterhuis, P. Konik, I. Cervenka, T. Polonio, P. Krejci, G. Schulte, V. Bryja, *J. Biol. Chem.* 286 (2011) 10396–10410.
- [23] V. Bryja, A. Schambony, L. Cajanek, I. Dominguez, E. Arenas, G. Schulte, *EMBO Rep.* 9 (2008) 1244–1250.
- [24] J.A. Lewis, J.T. Fleming, *Methods Cell Biol.* 48 (1995) 3–29.
- [25] Q. Ch'ng, L. Williams, Y.S. Lie, M. Sym, J. Whangbo, C. Kenyon, *Genetics* 164 (2003) 1355–1367.
- [26] G. Esposito, E. Di Schiavi, C. Bergamasco, P. Bazzicalupo, *Gene* 395 (2007) 170–176.
- [27] R.S. Kamath, A.G. Fraser, Y. Dong, G. Poulin, R. Durbin, M. Gotta, A. Kanapin, N. Le Bot, S. Moreno, M. Sohrmann, D.P. Welchman, P. Zipperlen, J. Ahringer, *Nature* 421 (2003) 231–237.
- [28] J.F. Rual, J. Ceron, J. Koreth, T. Hao, A.S. Nicot, T. Hirozane-Kishikawa, J. Vandenhaute, S.H. Orkin, D.E. Hill, S. van den Heuvel, M. Vidal, *Genome Res.* 14 (2004) 2162–2168.
- [29] J.N. Maloof, J. Whangbo, J.M. Harris, G.D. Jongeward, C. Kenyon, *Development* 126 (1999) 37–49.
- [30] H.C. Korswagen, M.A. Herman, H.C. Clevers, *Nature* 406 (2000) 527–532.
- [31] J. Hu, Y.K. Bae, K.M. Knobel, M.M. Barr, *Mol. Biol. Cell* 17 (2006) 2200–2211.
- [32] M.J. Lorenowicz, M. Macurkova, M. Harterink, T.C. Middelkoop, R. de Groot, M.C. Betist, H.C. Korswagen, *Cell. Signal.* 26 (2014) 19–31.
- [33] M.A. Hilliard, C.I. Bargmann, *Dev. Cell* 10 (2006) 379–390.
- [34] M. Silhankova, H.C. Korswagen, *Curr. Opin. Genet. Dev.* 17 (2007) 320–325.
- [35] K. Willert, J.D. Brown, E. Danenberg, A.W. Duncan, I.L. Weissman, T. Reya, J.R. Yates 3rd, R. Nusse, *Nature* 423 (2003) 448–452.
- [36] S. Sarno, H. Reddy, F. Meggio, M. Ruzzene, S.P. Davies, A. Donella-Deana, D. Shugar, L.A. Pinna, *FEBS Lett.* 496 (2001) 44–48.
- [37] G.K. Scott, H. Fei, L. Thomas, G.R. Medigeshi, G. Thomas, *EMBO J.* 25 (2006) 4423–4435.
- [38] F. Delom, D. Fessart, *Int. J. Cell Biol.* 2011 (2011) 246954.
- [39] P. Liberali, P. Ramo, L. Pelkmans, *Annu. Rev. Cell Dev. Biol.* 24 (2008) 501–523.
- [40] D. Bar-Zvi, D. Branton, *J. Biol. Chem.* 261 (1986) 9614–9621.
- [41] Y.M. Kim, L.S. Barak, M.G. Caron, J.L. Benovic, *J. Biol. Chem.* 277 (2002) 16837–16846.
- [42] V.I. Korolchuk, G. Banting, *Traffic* 3 (2002) 428–439.
- [43] M. Galovic, D. Xu, L.B. Areces, R. van der Kammen, M. Innocenti, *J. Cell Sci.* 124 (2011) 2001–2012.
- [44] M. Ruzzene, L.A. Pinna, *Biochim. Biophys. Acta* 1804 (2010) 499–504.